Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer

At the 2017 Gastrointestinal Cancers Symposium, researchers presented the exciting new study that treatment with nivolumab (Opdivo) reduces the risk of death by 37% for patients with advanced gastric or gastroesophageal junction (GEJ) cancer following second or later-line chemotherapy.